LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Uždarymo kaina

29.83 1.02

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.88

Max

29.99

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+111% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-6.7M 1.4B
Ankstesnė atidarymo kaina	28.81
Ankstesnė uždarymo kaina	29.83

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

27.895 / 30.16 Palaikymas ir pasipriešinimas

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-21 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164 Million

2026-05-21 16:49; UTC

Uždarbis

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

2026-05-21 16:26; UTC

Pagrindinės rinkos jėgos

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

2026-05-21 23:51; UTC

Rinkos pokalbiai

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

2026-05-21 23:37; UTC

Uždarbis

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

2026-05-21 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-21 23:30; UTC

Rinkos pokalbiai

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

2026-05-21 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Conduent to Sell Public Transit Business to Modaxo for $164M

2026-05-21 21:53; UTC

Uždarbis

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

2026-05-21 21:02; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

2026-05-21 20:55; UTC

Uždarbis

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

2026-05-21 20:30; UTC

Karštos akcijos

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

2026-05-21 20:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-21 20:20; UTC

Rinkos pokalbiai

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Adj EPS 3c >BULL

2026-05-21 20:20; UTC

Uždarbis

Webull 1Q Rev $159.9M >BULL

2026-05-21 20:18; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Easing in Early May -- Market Talk

2026-05-21 20:18; UTC

Uždarbis

Webull 1Q Loss/Shr 4c

2026-05-21 19:43; UTC

Rinkos pokalbiai

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-21 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

2026-05-21 18:58; UTC

Uždarbis

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

2026-05-21 18:15; UTC

Rinkos pokalbiai

Gold Higher For Second Consecutive Day -- Market Talk

2026-05-21 17:40; UTC

Rinkos pokalbiai

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

2026-05-21 17:04; UTC

Rinkos pokalbiai

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

2026-05-21 17:01; UTC

Uždarbis

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

2026-05-21 16:20; UTC

Rinkos pokalbiai

Uždarbis

Stellantis Targets Distant but Constructive -- Market Talk

2026-05-21 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

111% į viršų

12 mėnesių prognozė

Vidutinis 62.33 USD 111%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

27.895 / 30.16Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.